Journal
SEMINARS IN IMMUNOLOGY
Volume 22, Issue 3, Pages 162-172Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2010.02.003
Keywords
Allogeneic; Leukemia-targeted; T-cell; Immunotherapy
Categories
Funding
- NCI [CA23766, CA106450]
- Aubrey Foundation
- Clair Tow Chair in Pediatric Oncology Research
- Laura Rosenberg Foundation
- Major Family Foundation
Ask authors/readers for more resources
Adoptive transfer of in vivo generated antigen-specific donor-derived T-cells is increasingly recognized as an effective approach for the treatment or prevention of EBV lymphomas and cytomegalovirus infections complicating allogeneic hematopoietic cell transplants. This review examines evidence from preclinical experiments and initial clinical trials to critically assess both the potential and current limitations of adoptive transfer of donor T-cells sensitized to selected minor alloantigens of the host or to peptide epitopes of proteins, differentially expressed by clonogenic leukemia cells, such as the Wilms tumor protein, WT-1, as a strategy to treat or prevent recurrence of leukemia in the post-transplant period. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available